

10) Congenital Hyperinsulinism (HI) includes many subtypes that all cause hypoglycemia due to the overproduction of insulin, which can lead to permanent brain damage or death. The consequences of HI are preventable – however, HI is often overlooked, misdiagnosed, or even when detected, mistreated. We are seeking applications for an innovative clinical or pre-clinical study that has the potential to benefit patients living with HI and should lead to: (1) an improved treatment; (2) novel endpoints for evaluating efficacy of treatments; (3) a better understanding of the patient experience including difficulty with feeding, fear of hypoglycemia, or the patient experience in resource limited settings; (4) knowledge of the cause of neurological damage; (5) novel or more effective methods for diagnosing hyperinsulinism at or near birth; or (6) enhanced management for HI. Multi-institution or multi-center collaboration is highly encouraged. Proposals that have the potential to benefit patients with all types of HI will be prioritized. The HI Global Registry (HIGR) is a global patient-powered congenital hyperinsulinism patient registry and consists of a series of thirteen surveys made up of questions related to a patient's HI experience over their lifetime (<https://www.higlobalregistry.org/>). It is highly recommended that HIGR be used as one of the data sources or tools to collect study data. Applicants are encouraged to contact CHI to explore how to utilize HIGR. Please contact research@congenitalhi.org if you would like to discuss your proposed project. One grant of \$70,920 is made possible by Team CHIbra and Congenital Hyperinsulinism International.